You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》科济药业(02171.HK)下周一起招股 引入礼来等9名基投
阿思达克 06-04 17:54
内地生物制药公司科济药业(02171.HK)公布招股详细,计划发行9,474.7万股,当中10%为本地发售,90%为国际配售,每股招股价介乎29.6至32.8元,集资最多约31.07亿元。每手500股入场费约16,565.26元,联席保荐人为高盛及瑞银。

招股期由下周一(7日)起至下周四(10日)结束,料於6月18日上市。是次招股共引入9名基石投资者,包括礼来亚洲基金、新华人寿、CloudAlpha、睿远、WT基金、广发证券、Dymon Asia、常春藤及南方基金,合共认购约17.85亿元或2.3亿美元等值股份,设6个月禁售期。

财务高级副总裁谢岚表示,由於公司尚未有产品商业化,因此过往几年录得经营亏损,去年度亏损达10.64亿元人民币,料於明年上半年就核心产品CT053提交中国新药上市申请。

问到与热门新股时代天使(06699.HK)撞期,董事会主席、首席执行官兼首席科学官李宗海称,每家公司都有特点,投资者亦有不同关注重点,又指在研产品於临床实验中显示出有疗效及安全性,相信会得到市场认可。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account